A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.

Eyetech Pharmaceuticals

Status and phase: Completed; Phase 3; Phase 2

Conditions: Age-Related Macular Degeneration

Treatments: Drug: Pegaptanib sodium

Study type: Interventional

Funder types: Industry

Identifiers

NCT00321997

EOP1003 and EOP1004

Details and patient eligibility

About

The purpose of this study is to compare the ability of different doses of pegaptanib sodium to safely and effectively minimize fluid leakage within the eye, thereby stabilizing or impriving vision in patients with wet AMD when compared to placebo injections.

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Subjects of either gender, aged 50 years or greater. Subfoveal choroidal neovascularization (CNV) due to AMD. Best corrected visual acuity in the study eye between 20/40 and 20/320.

Exclusion criteria

Any prior subfoveal thermal laser therapy.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind